Candidemia Lab Survey

Emerging Infections Program

Att14_Laboratory Survey Candidemia_FINAL_highlighted with OMB No

HAIC Candidemia Periodic Laboratory Survey

OMB: 0920-0978

Document [pdf]
Download: pdf | pdf
Lab ID No. [][][][][][]

Form Approved OMB No. 092-0978

2021 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE
1) What kind of laboratory is this facility? (select one)
Hospital laboratory
Commercial laboratory (Quest, etc.)

Other (specify) ______________________
Unknown

2) Does this facility ever receive blood cultures from nursing homes or other long term care facilities?
Yes
No
Unknown
3) Does the clinical microbiology laboratory at your institution have a separate Mycology section or laboratory?
Yes
No
Unknown
4) What kind of blood culture system does your laboratory use? (check all that apply)
BacT/Alert
Bactec FX
BacT/Alert 3D
Isolator tubes
VersaTREK
Other (specify) ______________________
Bactec 9240
5) What is the approximate volume of any type of fungal cultures performed annually in your laboratory?
Specify number: ______________
Unknown
6) What is the approximate volume of fungal cultures from blood performed annually in your laboratory?
Specify number: ______________ Unknown
YEAST IDENTIFICATION
7) Does this laboratory offer yeast identification either onsite or sent to another laboratory?
Yes
No (-------- If No, SKIP TO QUESTION 15 --------)
Unknown (is there another laboratory staff member who can assist with the questionnaire?)
8) Where is yeast identification done? (check the most applicable)
On-site, in the laboratory
Sent to commercial lab
Sent to affiliated hospital lab
Sent to other local/regional, non-affiliated reference or public health laboratory
Other ______________________________
Unknown

Answer the following questions for the lab selected in question 8.
9) How does this lab identify yeast? (check all that apply)
MALDI-TOF Bruker (Biotyper)
MALDI-TOF bioMerieux (VITEK MS)
VITEK 2
API 20C
DNA sequencing
PNA-FISH
BactiCard Candida

BD Phoenix
MicroScan
RapID Plus
Other (specify) ______________________
Unknown

10) Does this laboratory routinely use Chromagar for the identification or differentiation of Candida isolates?
Yes
No
Unknown
11) Species-level identification is performed for Candida spp. isolated from which of the following?
a. Blood isolates
Yes, reflexively

Yes, with clinician order

No

Unknown

Public reporting burden of this collection of information is estimated to average 11 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing
and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this
burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (09200978).

2021

Page 1 of 4

Lab ID No. [][][][][][]
b. Other normally sterile body site isolates
Yes, reflexively
Yes, with clinician order
c. Abdominal isolates
Yes, reflexively
Yes, with clinician order

No

Unknown

No

Unknown

d. Respiratory isolates
Yes, reflexively

Yes, with clinician order

No

Unknown

e. Urine isolates
Yes, reflexively

Yes, with clinician order

No

Unknown

Other (specify) ____________________
Yes, reflexively
Yes, with clinician order

No

Unknown

f.

12) Does this laboratory employ the T2Candida Panel to identify Candida from blood specimens?
Yes (got to 12a)
No (go to 13)
Unknown
a. If Yes, when did this lab first start using T2Candida Panel? Date (mm/dd/yyyy): ____/____/________
b. I f Yes, does this lab culture blood if you get a positive result on T2Candida Panel?
Yes, reflexively
No
Yes, with a clinical order
Unknown
13) Does this laboratory employ the BioFire (FilmArray) to identify Candida from blood culture?
Yes (go to 13a)
No (go to 14)
Unknown
a. If Yes, when did this lab first start using BioFire? Date (mm/dd/yyyy): ____/____/________
14) If No for both Question 12 and 13, does this laboratory have plans to employ culture-independent diagnostics
for Candida identification in the near future (e.g. T2Candida Panel, BioFire)?
Yes
Unknown
No
Not applicable
ANTIFUNGAL SUSCEPTIBILITY TESTING
15) Does this laboratory offer any antifungal susceptibility testing for Candida either onsite or sent to another
laboratory?
Yes
No (-------- If No, QUESTIONNAIRE COMPLETE --------)
Unknown (is there another laboratory staff member who can assist with the questionnaire?)
16) Where is antifungal susceptibility testing (AFST) done? (check the most applicable)
On-site, in the laboratory
Sent to commercial lab
Sent to affiliated hospital lab
Sent to other local/regional, non-affiliated reference or public health laboratory
Other ______________________________
Unknown

Answer the following questions for the lab selected in question 16.
17) Is antifungal susceptibility testing available for any of the following antifungal drugs (check all that apply):
Fluconazole
Caspofungin
Voriconazole
Amphotericin B
Itraconazole
Flucytosine
Posaconazole
Other (specify) __________________
Micafungin
Unknown
Anidulafungin

2021

Page 2 of 4

Lab ID No. [][][][][][]
18) What methods are used for AFST? (check all that apply)
Non-commercial broth microdilution
YeastOne
E test

Vitek
Other ______________________________
Unknown

a. If you use Vitek for AFST, what Candida species do you test with it? (check all that apply)
C. albicans
C. parapsilosis
C. glabrata
Other Candida spp.
19) How are results of AFST reported? (select one)
Categorical interpretation only (susceptible,
resistant, etc.)
MIC only

Both--categorical interpretation PLUS MIC
Unknown

a. If categorical interpretation only, how do you determine the categorical interpretation? (check all that
apply)
CLSI M27 S4
Apply epidemiologic breakpoints
CLSI M27 S3
Other ______________________________
From manufacturer of MIC test
20) For what type of Candida isolates is antifungal susceptibility testing (AFST) performed
automatically/reflexively? (check all that apply)
Blood isolates
No AFST performed automatically (requires
Other normally sterile body site isolates
order from a clinician)
Other (specify) ______________________
Unknown
21) How is AFST performed for the following Candida spp.?
a. C. albicans
Performed automatically/reflexively (Go to 21ai)
Performed with a clinician’s order (Go to 21ai)
Not performed
i.

Drugs for which AFST is performed on C. abicans (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

b. C. glabrata
Performed automatically/reflexively (Go to 21bi)
Performed with a clinician’s order (Go to 21bi)
Not performed
i.

Drugs for which AFST is performed on C. glabrata (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

c. C. parapsilosis
Performed automatically/reflexively (Go to 21ci)
Performed with a clinician’s order (Go to 21ci)
Not performed
i.

2021

Drugs for which AFST is performed on C. parapsilosis (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

Page 3 of 4

Lab ID No. [][][][][][]
d. Other Candida spp.
Performed automatically/reflexively (Go to 21di)
Performed with a clinician’s order (Go to 21di)
Not performed
i.

Drugs for which AFST is performed on other Candida spp. (check all that apply):
Micafungin
Fluconazole
Other
Anidulafungin
Voriconazole
Unknown
Caspofungin
Amphotericin B

------------------------------------------------ END OF QUESTIONNAIRE ------------------------------------------------

2021

Page 4 of 4


File Typeapplication/pdf
File TitleCandidemia 2009 Laboratory Practice Survey
AuthorAngela Ahlquist
File Modified2020-08-27
File Created2020-08-27

© 2024 OMB.report | Privacy Policy